Who is sponsoring NCT04992455?

NCT04992455 is sponsored by Namik Kemal University.

What drugs are being tested in NCT04992455?

Interventions in NCT04992455: Older Patients Receiving Chemotherapy.

What condition does NCT04992455 study?

NCT04992455 studies Predicting Chemotherapy Related Toxicity in Elderly Patients.

Is NCT04992455 still recruiting?

NCT04992455 is currently status unknown. Last updated 5 August 2021.

Last reviewed 2021-08-05 · How we verify

NCT04992455

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

G8, VES-13 and CARG Scores in Predicting Chemotherapy Toxicity in Geriatric Cancer Patients

Status unknown Last updated 5 August 2021

What this trial tests

trial testing Older Patients Receiving Chemotherapy in Predicting Chemotherapy Related Toxicity in Elderly Patients in 150 participants. Status unknown.

Timeline

1 February 2021

Primary endpoint
1 September 2021

1 September 2021

Quick facts

Lead sponsor	Namik Kemal University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	150
Start date	1 February 2021
Primary completion	1 September 2021
Estimated completion	1 September 2021
Sites	1 location across Turkey (Türkiye)

Drugs / interventions tested

Older Patients Receiving Chemotherapy

Conditions studied

Predicting Chemotherapy Related Toxicity in Elderly Patients — all drugs for Predicting Chemotherapy Related Toxicity in Elderly Patients →

Sponsor

Namik Kemal University

Who can join

65 and older, any sex, with Predicting Chemotherapy Related Toxicity in Elderly Patients. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

All participants' medical information will be collected for use as a baseline, including tumor-specific variables, nutritional status, functional status, psychological status, cognitive function, social support, and comorbidities. The suitability of G8, VES-13 and CARG chemotherapy risk assessment tools for elderly cancer patients was investigated.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Namik Kemal University trials

Trials by the same sponsor.

NCT07349862 — Flipped Learning in Nursing Education · NA · enrolling by invitation
NCT07348549 — Gagne Learning Model in Nursing Education · NA · enrolling by invitation
NCT07467304 — Nursing Education Provided After Cesarean Section Surgery. · NA · enrolling by invitation
NCT05671484 — TFPB vs QLB III in Infra-umbilical Pediatric Surgeries · NA · completed
NCT05928845 — Sternocleidomastoid Thickness in Sarcopenia · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04992455 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Namik Kemal University
Last refreshed: 5 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04992455.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing